Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Regular update of the Norwegian Laboratory Code System released

In late May 2023, the Norwegian Directorate of e-Health released an updated version of the Norwegian Laboratory Code (NLK) system to be implemented no later than July 1, 2023. The document with the allocation of new codes to reimbursement categories is not yet available. NLK system is used for activity-based reimbursement by the Norwegian Health Economics Administration (Helfo) for laboratory tests performed in outpatient settings.

A total of 142 new codes were added to NLK in medical biochemistry, clinical pharmacology, and medical microbiology fields. Some examples of the newly-added codes are:

  • NPU19053 DNA CYP21A2 gene;
  • NPU62051 Sp-Cytomegalovirus (CMV) IgG production (spinal fluid);
  • NPU58983 Us-Haemophilus influenza DNA (unspecified);
  • NPU62030 B-Yersinia pestis DNA (blood);
  • NPU62020 B-West Nile virus RNA (blood);
  • NPU62021 B-Yellow fever virus RNA (blood);
  • NPU62036 P-Broad substance search (plasma).

Furthermore, 33 codes were terminated, and 122 codes were amended

See more information in Norwegian here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.eks).